Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Park Medi World Limited

NSE: PARKHOSPSHospital

Share price

₹270.80

+3.81% close of 9 Oct 2026

Market cap ₹11,686 CrP/E 40.2 (as of 8 Oct 2026)

Price-based ratios (P/B, dividend yield, EV/EBITDA) are as of 8 Oct 2026, the close above is 9 Oct 2026.

Business score

How strong the business is, in one number. The parts behind it are in Pro.

67

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹11,686 Cr

P/E ratio

40.2

P/B ratio

5.8

ROCE

19.5%

ROE

16.8%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 9 Oct 2026 close52-week high ₹299.3052-week low ₹143.92

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Fewer than three years of filings — too early to judge growth.

Whether it grew faster than its sector

It grew 14.2% a year against a sector median of 13.1% — 1.2 percentage points faster.

Room to re-rate, or risk of de-rating

Too little price history yet to compare it with its own past.

Whether growth justifies the valuation

Priced at 8.0 times its growth rate, on earnings growth of 5%.

Profit growthPrice per ₹1 profitPer 1% growth
Park Medi World Limited — this one5%/yr40.2×₹8.0
Apollo Hospitals32%/yr52.5×₹1.6
MANIPALHOS22%/yr101.7×₹4.6
Max Healthcare Institute10%/yr56.8×₹5.7
Aster DM Healthcare Limited-1%/yr163.5×—
Fortis Healthcare Limited27%/yr54.0×₹2.0

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Hospital), it ranks 6 of 24 on returns, 17 of 23 on growth, 9 of 25 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 19.5% on capital, ahead of 75% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹1265 crore of cash from the business and spent ₹517 crore on plant and equipment, with ₹748 crore to spare; it still raised ₹66 crore from shareholders — borrowings did not rise. And the profit is real: of every 100 rupees it reported over 6 years, about 119 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back faster than it used to: it went from being waiting 60 days for its cash to waiting 28 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

8 of 9 checks clear · 89%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Revenue up 19% and profit up 35%, with the March-2028 bed target raised to 5,740.

Announced 3 Aug 2026 · Consolidated · Unaudited

Revenue

₹476 Cr

Revenue vs last year

+19.2%

Revenue vs last quarter

+3.4%

Net profit

₹89 Cr

Profit vs last year

+34.2%

Profit vs last quarter

+15.1%

Net margin

18.6%

EPS

₹2.05

Earnings call transcript · 4 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹11,686 Cr
Prev close
₹270.80
52w High
₹305
52w Low
₹138
Enterprise value
₹11,150 Cr
Beta
0.9
Price CAGR 1y
—
Price CAGR 3y
—
Price CAGR 5y
—
Price CAGR 10y
—

Ratios

Return on assets
9.8%
PEG ratio
8.4
P/E ratio
40.2
P/B ratio
5.8
EV / EBITDA
24.0
Industry P/E
54.3
ROCE
19.5%
ROCE 5y average
25.6%
ROE
16.8%
Debt / Equity
0.2
Interest coverage
6.8
Dividend yield
0.0%
ROE 3y average
19.0%
ROE last year
17.0%

Annual P&L

Annual revenue
₹1,679 Cr
Annual profit
₹274 Cr
Operating margin
27.0%
Net profit margin
16.3%
EBITDA margin
26.6%
Sales growth 3y
10.2%
Sales growth 5y
17.0%
Profit growth 3y
5.0%
Profit growth 5y
11.0%
EPS
₹6.0
Sales growth TTM
21.0%
Profit growth TTM
27.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹476 Cr
Profit latest quarter
₹89 Cr
YoY quarterly sales growth
19.3%
YoY quarterly profit growth
34.8%
OPM latest quarter
26.5%

Balance Sheet

Book Value
₹47.0
Face Value
₹2.0
Total debt
₹364 Cr
Total cash
₹431 Cr
Borrowings
₹364 Cr
Reserves / Equity
22.5

Cash Flow

Operating cash flow
₹329 Cr
Free cash flow
₹209 Cr
FCF yield
1.3%
Net cash flow
₹134 Cr

Shareholding

Promoter holding
82.9%
FII holding
0.8%
DII holding
8.9%
Public holding
7.3%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Apollo Hospitals7,700.0052.61,10,7140.25610.434.27,043.520.617.4
Manipal Health689.35102.490,6760.00243.4-7.93,090.638.112.1
Max Healthcare877.3557.085,3930.22323.04.92,366.216.714.7
Aster DM Quality677.00163.559,0120.4429.3-46.11,310.721.611.6
Fortis Health.766.5554.357,8710.13272.83.42,545.017.513.4
Narayana Hrudaya1,712.6540.635,0000.26207.35.72,683.678.015.5
Global Health1,286.2060.434,5830.04157.3-0.21,304.126.517.4
Park Medi World265.7541.311,4790.0088.642.3475.719.319.5
Median396.7747.95,6870.0230.219.9399.422.314.7

Competes with: Apollo Hospitals, Aster DM Healthcare Limited, Fortis Healthcare Limited, Global Health Limited, Krishna Institute of Medical Sciences Limited, MANIPALHOS, Max Healthcare Institute, Narayana Hrudayalaya Ltd.

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemSep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales692348354399410410460476
Expenses265265294297311333350
Material Cost767877
Change in Inventories-0.101.19-0.87
Purchases of Stock-in-Trade000
Employee Cost838692
Other Expenses152167181
Operating Profit838810511399127126
OPM %2724252627242827
Other Income15978988
Exceptional items (within Other Income)000
Interest16161515151410
Depreciation15161515151819
Profit before tax6766829178103105
Tax %32202014322616
Net Profit46526679537789
EPS in Rs2.971.171.511.911.171.641.91
Diluted EPS in Rs1.351.782.05

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7661,0841,2551,2311,3941,6791,756
Expenses4577408639191,0201,2331,291
Material Cost295
Change in Inventories0.75
Purchases of Stock-in-Trade0
Employee Cost323
Other Expenses616
Operating Profit309345391312374446466
OPM %40323125272727
Other Income391529303232
Exceptional items (within Other Income)0
Interest24405172626153
Depreciation24354151576267
Profit before tax265278315218286355378
Tax %262828302523
Net Profit187199228152215274297
EPS in Rs8112149.985.255.986.63
Diluted EPS in Rs6.87
Dividend Payout %000000

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
17%
3 years
10%
TTM
21%

Compounded profit growth

10 years
—
5 years
11%
3 years
5%
TTM
27%

Return on equity

10 years
—
5 years
24%
3 years
19%
Last year
17%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital197777777786
Reserves2563806108069751,936
Borrowings292517576687682364
Other Liabilities249319331343393411
Minority Interest82
Total Liabilities8161,2931,5931,9122,1272,797
Fixed Assets3654585368378901,309
CWIP72953237123
Investments000000
Other Assets4438061,0521,0431,1991,365
Total Assets8161,2931,5931,9122,1392,813

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity223155199367215329
Cash from Investing Activity-233-248-234-76-100-316
Cash from Financing Activity491631-130-89121
Net Cash Flow3970-3416126134
Free Cash Flow866410629970209

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days151151168151161129
Inventory Days47143334
Days Payable121101110133176134
Cash Conversion Cycle77646121-12-2
Working Capital Days406040213028
ROCE %3831202019

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemDec 2025Mar 2026Jun 2026
Promoters838383
FIIs1.280.860.82
DIIs8.588.958.95
Government0.200.300
Public7.066.987.33
No. of Shareholders1,14,60050,86352,428

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year +83.0% (₹147.95 → ₹270.80)Brick size ₹9.08 (fixed)Bricks 22
₹150₹200₹250₹271Feb '26May '26Oct '26
Price moved up one brickPrice moved down one brickLast close ₹270.80 on 9 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

net debt from the filed balance sheet at the newest year end: Borrowings − Cash Equivalents − Investments (Current); negative = net cash

-67.00inr_cr

2026-03-31

room / bed occupancy %

56.00pct

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

stores / outlets at period end

17.00count

2026-06-30

News

News and filings about Park Medi World Limited. Open one to see why it matters.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Hospital
Classification
Healthcare › Hospital
ISIN
INE119201023

News impact

Big market events that reach Park Medi World Limited, and how the effect spreads.

No recent market events reach this company.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Splits, bonuses & buybacks

  • daily-prices repair: 2 rows from NSE's archive (replace 0, delete 1, insert 1), 2026-01-15..2026-02-01 (docs/flat_day_repair.md)1× · 15 Jan 2026

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.